CD200R1 and systemic lupus erythematosus: Although the anti-inflammatory potential of CD200R1 agonist was demonstrated to limit the LPS-induced inflammation of human renal proximal tubular epithelial cells [109], the clinical efficacy of treating SLE or LN via this approach requires further elucidation.